Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Israel health ministry has approved the licensing of a generic version of AbbVie’s HIV drug Kaletra to treat Covid-19, as the cases in the country exceed 500.
The patent for the anti-viral drug Kaletra expires in Israel in 2024, while the patent in other countries, including India, already expired.
Israel attorney general for the first time allowed the use of a generic version of a patent-protected drug, noted Reuters. To protect the patent, the generic medication, imported from countries where patent expired, will not be given to HIV patients but only be used for treating the novel coronavirus infection.